Histological findings to five years after early conversion of kidney transplant patients from cyclosporine to everolimus: an analysis from the randomized ZEUS study
Open Access
- 28 June 2018
- journal article
- research article
- Published by Springer Nature in BMC Nephrology
- Vol. 19 (1) , 154
Abstract
Conversion from calcineurin inhibitor (CNI) therapy to everolimus within 6 months after kidney transplantation improves long-term graft function but can increase the risk of mild biopsy-proven acute cellular rejection (BPAR). We performed a post-hoc analysis of histological data from a randomized trial in order to further analyze histologic information obtained from indication and protocol biopsies up to 5 years after transplantation. Biopsy samples obtained up to 5 years post-transplant were analyzed from the randomized ZEUS study, in which kidney transplant patients were randomized at month 4.5 to switch to everolimus (n = 154) or remain on cyclosporine (CsA)-based immunosuppression (n = 146). All patients received mycophenolate and steroids. At least one investigator-initiated biopsy was undertaken in 53 patients in each group between randomization and year 5, with a mean (SD) of 2.6 (1.7) and 2.2 (1.4) biopsies per patient in the everolimus and CsA groups, respectively. In the everolimus and CsA groups, investigator-initiated biopsies showed (i) BPAR in 12.3 and 7.5% (p = 0.182) of patients, respectively, with episodes graded mild in 22/24 and 18/20 cases (ii) CsA toxicity lesions in 4.5 and 10.3% of patients (p = 0.076) (iii) antibody-mediated rejection in 0.6 and 2.7% of patients (p = 0.204), respectively. This analysis of histological findings in the ZEUS study to 5 years after kidney transplantation shows no increase in antibody-mediated rejection under everolimus-based therapy with a lower rate of CNI-related toxicity compared to a conventional CsA-based regimen, and confirms the preponderance of mild BPAR seen in the main study after the early switch to CsA-free everolimus therapy. ClinicalTrials.gov NCT00154310 . Date of registration: September 12, 2005.Keywords
Funding Information
- The ZEUS study was funded by Novartis Pharma GmbH, Nuernberg, Germany
This publication has 20 references indexed in Scilit:
- Diagnosis and prevention of chronic kidney allograft lossThe Lancet, 2011
- Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trialThe Lancet, 2011
- Protocol Biopsies in Renal Transplantation: Insights into Patient Management and PathogenesisAmerican Journal of Transplantation, 2007
- No Difference in Degree of Interstitial Sirius Red–Stained Area in Serial Biopsies from Area under Concentration-over-Time Curves–Guided Cyclosporine versus Tacrolimus-Treated Renal Transplant Recipients at One YearJournal of the American Society of Nephrology, 2006
- Predicting Subsequent Decline in Kidney Allograft Function from Early Surveillance BiopsiesAmerican Journal of Transplantation, 2005
- Baseline Immunosuppression is Associated with Histological Findings in Early Protocol BiopsiesTransplantation, 2004
- The Natural History of Chronic Allograft NephropathyNew England Journal of Medicine, 2003
- Subclinical Rejection in Tacrolimus-Treated Renal Transplant RecipientsTransplantation, 2002
- HISTOLOGIC FEATURES OF CHRONIC ALLOGRAFT NEPHROPATHY REVEALED BY PROTOCOL BIOPSIES IN KIDNEY TRANSPLANT RECIPIENTSTransplantation, 1998
- HISTOLOGICAL FINDINGS IN EARLY ROUTINE BIOPSIES OF STABLE RENAL ALLOGRAFT RECIPIENTSTransplantation, 1994